All of Crossject's employees work every day as a team to develop innovative life-saving solutions and make them a reality for patients. Our approach to the administration of emergency medicines mobilizes not only our teams but also our industrial and financial partners to act on a patient life-saving mission across the world.
Our needle-free device ZENEO® simplifies the patient-side management of disorders requiring auto-injectables.
Our expertise gives us a head start but also inspires us to act responsibly for our patients and their family.
With our unique know-how, we aim to become a world leader in the self-administration of emergency needle free injectables.
From the solid foundation of its unmatched technology, Crossject aims to become the world's leading pharmaceutical laboratory for emergency needle free auto-injectables.
Today, after 20 years of focused R&D, Crossject offers an auto-injection device protected by 400 patents until 2037.
To always move forward, Crossject has united a vanguard team of specialists from a range of industries and thus gathered the expertise it needs to empower each step of its evolution.
To save lives simply
The needle-free auto-injection system ZENEO® will save people in emergency situations.
Crossject a signé en octobre 2019 la charte Responsible Care®, engagement commun de l’industrie chimique mondiale, pour acter de son implication dans la responsabilité sociétale des entreprises.
Un des objectifs stratégiques de CROSSJECT est d’intégrer la démarche RSE comme élément puissant de l’accompagnement du changement de dimension industrielle de l’entreprise.